[ad_1]
Good news for United States President Donald Trump on Friday night, as he announced that Ramsdivir had the green light to treat Corona. The United States Food and Drug Administration (FDA) has authorized the manufacturer, Gilead Sciences, for emergency use of its experimental antiviral treatment to treat people with Covid-19 disease.
The drug provided a glimmer of hope in the fight against SK this week when the results of a promising clinical trial were published. The Cleveland Medical Center announced that the drug had proven effective in controlling the virus and had reduced recovery time to 4 days.
Meanwhile, the manufacturer pledged to “provide adequate supplies for patients worldwide.”
What is Ramdesiver and why was it developed?
It is an experimental antiviral medication that was first developed by the American pharmaceutical company Gilliad Sciences for the treatment of Ebola.
Developed in 2015, Ramsdivir demonstrated the first promises in an animal study and was later released in the Congo, but ultimately failed as an effective treatment for Ebola.
Speaking to the New York Post, former Assistant Commissioner of the Food and Drug Administration Peter Bates said: “He never made a promise. He failed relatively against Ebola. So doctors said let’s see if he works against Covid-19.” .
How effective is it against the crown?
The results of a clinical trial conducted on more than 1,000 people showed that Covid-19 patients with respiratory problems improved 31% faster than those taking the placebo, according to the National Institute of Allergy and Infectious Diseases.
However, Bates cautioned that the drug showed benefits only in elderly hospitalized patients with previous or respiratory health problems. He said, “It saves lives, but it doesn’t change the rules of the game. Clinical trials have shown that it has led to recovery in 4-10% of patients with severe illness.”
How does it work
To do the job, the drug simulates adenosine, one of the four basic components of viral RNA, also known as RNA, and when the virus integrates Ramsdevir into its genome instead of adenosine, it becomes unable to reproduce, according to the agency France -Presse.
As Bates explains: “It enters the viral RNA and causes the virus to end prematurely.”
According to the results of the most recent study published by Gilliad Sciences, the most common adverse reactions were nausea and acute respiratory failure. About 7% of patients experienced an increase in liver enzymes.
How much will it cost?
This is still unclear, though Gilliad Sciences CEO Daniel Oday told Stat News this week that the company is donating 1.5 million doses of the drug, about 140,000 courses of treatment, to hospitals.
Odai added that the company pledged “to work with the government and healthcare systems to ensure access to the drug and make it accessible to governments in the future.”
“Still experimental”
Doctors say they need to know more about it. Some experts also consider it “a good guide” that could pave the way for better treatments.
“Clinical trials have shown a very positive effect on inpatients. But for now, it is still an experimental drug,” said Peter Bates, a former assistant commissioner for the Food and Drug Administration.
It is noteworthy that, in addition to “hydroxychloroquine”, “Ramsdevir” is one of the options currently offered with a group of antivirals.
However, the US Food and Drug Administration. The US, the European Union Medicines Control Authority, the Canadian Health Service and the French Medicines Agency have recently warned against the use of “hydroxychloroquine”, pointing to side effects that include severe heartbeat and rapid acceleration.
");
//}, 3000);
}
});
//$(window).bind('scroll ');
$ (window) .scroll (function () {
if (alreadyLoaded_facebookConnect == false) {
alreadyLoaded_facebookConnect = true;
// $ (window) .unbind ('scroll');
// console.log ("loaded offset");
(function (d, s, id) {
var js, fjs = d.getElementsByTagName (s)[0];
if (d.getElementById (id)) return;
js = d.createElement (s); js.id = id;
js.async = true;
js._https = true;
js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322";
fjs.parentNode.insertBefore (js, fjs);
} (document, 'script', 'facebook-jssdk'));
// pre_loader ();
// $ (window) .unbind ('mousemove');
// setTimeout (function () {
// $ ('# boxTwitter'). html ("Tweets from @tayyar_org");
//}, 3000);
var scriptTag = document.createElement ("script");
scriptTag.type = "text / javascript"
scriptTag.src = "https://news.google.com/scripts/social.js";
scriptTag.async = true;
document.getElementsByTagName ("head")[0].appendChild (scriptTag);
(function () {
$ .getScript ("https://news.google.com/scripts/social.js", function () {});
});
}
});
//$(window).load(function () {
// setTimeout (function () {
// // add the returned content to a newly created script tag
// var se = document.createElement ('script');
// se.type = "text / javascript";
// //se.async = true;
// se.text = "setTimeout (function () {pre_loader ();}, 5000);";
// document.getElementsByTagName ('body')[0].appendChild (se);
//}, 5000);
//});
[ad_2]
